PANTOPRAZOLE TABLET (DELAYED-RELEASE)

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

PANTOPRAZOLE (PANTOPRAZOLE SODIUM)

から入手可能:

MELIAPHARM INC

ATCコード:

A02BC02

INN（国際名）:

PANTOPRAZOLE

投薬量:

40MG

医薬品形態:

TABLET (DELAYED-RELEASE)

構図:

PANTOPRAZOLE (PANTOPRAZOLE SODIUM) 40MG

投与経路:

ORAL

パッケージ内のユニット:

100/500

処方タイプ:

Prescription

治療領域:

PROTON-PUMP INHIBITORS

製品概要:

Active ingredient group (AIG) number: 0133229001; AHFS:

認証ステータス:

CANCELLED POST MARKET

承認日:

2014-06-25

製品の特徴

PRODUCT MONOGRAPH
PR
PANTOPRAZOLE
Pantoprazole Sodium Delayed-Release Tablets, House Standard
(as pantoprazole 20 mg, 40 mg)
H
+
, K
+
-ATPase Inhibitor
MELIAPHARM INC.
6111 Royalmount Ave., Suite 100
Montréal, Québec
H4P 2T4
Date of Revision:
January 17, 2014
Submission Control No: 170312
_ _
_PANTOPRAZOLE Product Monograph _
_Page 2 of 39_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
..................................................................................................11
DOSAGE AND ADMINISTRATION
..............................................................................12
OVERDOSAGE
................................................................................................................13
ACTION AND CLINICAL PHARMACOLOGY
............................................................14
STORAGE AND STABILITY
..........................................................................................16
SPECIAL HANDLING INSTRUCTIONS
.......................................................................16
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................16
PART II: SCIENTIFIC INFORMATION
................................................................................17
PHARMACEUTICAL INFORMATION
..........................................................................17
CLINICAL TRIALS
...................................